RefinedScience is a precision medicine company arising from the Innovation Centers at the University of Colorado Anschutz Campus and UCHealth. It is devoted to identifying novel cellular targets as well as promising and safe new agents against treatment resistant cancers and other diseases. It accomplishes this by mining big data sets comprised of disease specific single cell omics data curated with accurate and deep clinical annotation on patient features including outcomes and treatment toxicities. The first example of this novel approach has been in the disease acute myeloid leukemia (AML) which represents an area of high unmet need as only a minority of patients with AML are cured and many live only a year or less. Findings from RefinedScience have led to the identification of multiple promising treatment targets on a growing range of leukemia stem cells, which in turn have led to a rapidly expanding IP portfolio, several pharma partnerships and the development of a new pharma company called OncoVerity. RefinedScience is devoted to overcoming other critical medical challenges like AML and is now expanding its unique team, infrastructure, and discovery engine to other disease areas with high unmet medical need.